ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Tocilizumab a “First Choice” for PHID Syndrome

Reuters Staff  |  October 30, 2017

NEW YORK (Reuters Health)—Tocilizumab should be the “first choice” for treatment of the autoinflammatory and cutaneous manifestations of pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, say clinicians from the U.K. PHID syndrome is an extremely rare autosomal recessive genetic disease caused by mutations in the SLC29A3 gene. Children with the syndrome develop patches…

U.S. Judge to Review Trump Healthcare Payments Cut

Dan Levine  |  October 23, 2017

SAN FRANCISCO (Reuters)—A U.S. judge is set to hear arguments on Monday about whether to block President Donald Trump’s decision to terminate controversial payments to health insurance companies under Obamacare. U.S. District Judge Vince Chhabria in San Francisco federal court has said he would quickly issue a ruling following the hearing. Several U.S. states sued…

GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

Ben Hirschler  |  October 23, 2017

LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…

FDA Teams with Medical Companies in Puerto Rico to Tackle Shortages

Reuters Staff  |  October 22, 2017

(Reuters)—The head of the U.S. Food and Drug Administration said the agency was working with several pharmaceutical and medical device companies in Puerto Rico to prevent shortages of medical products in the U.S. as it joins a massive effort to help rebuild the island that was ravaged by Hurricane Maria.1 Drugmakers are working to get…

Obamacare Whiplash Leaves States, Insurers with Dueling Price Plans

Caroline Humer  |  October 22, 2017

NEW YORK (Reuters)—President Donald Trump’s reversals in the past week on maintaining Obamacare subsidies to insurers are sowing new confusion over what kind of health insurance will be available to consumers, and at what price, when enrollment for 2018 begins in two weeks. Trump said last week his administration would stop paying billions of dollars…

Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD

Reuters Staff  |  October 22, 2017

NEW YORK (Reuters Health)—A biosimilar version of infliximab appears as effective as the original for treating pediatric inflammatory bowel disease (PIBD), and less costly, new research shows. “These baseline data have now enabled us to confidently switch patients from originator to biosimilar, adopting the same prospective methodology to monitor effectiveness, safety and cost,” Dr. Lisa…

U.S. Judge in Texas Invalidates Allergan Patents on Restasis

Jan Wolfe & Michael Erman  |  October 18, 2017

(Reuters)—A U.S. judge invalidated patents on Allergan Plc’.s dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company’s shares down more than 6%. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led…

U.S. Senators Reach Bipartisan Deal on Obamacare Backed by Trump

Yasmeen Abutaleb & Richard Cowan  |  October 18, 2017

WASHINGTON (Reuters)—On Tuesday, two U.S. senators announced a bipartisan breakthrough to shore up Obamacare for two years by reviving federal subsidies for health insurers that President Donald Trump planned to scrap, and the president voiced support for the plan. The agreement worked out by Sen. Lamar Alexander (R-Tenn.) and Sen. Patty Murray (D-Wash.) would meet…

GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada

Reuters Staff  |  October 16, 2017

(Reuters)—Canadian health regulators have approved GlaxoSmithKline’s shingles vaccine, the company said on Friday.1 Shingrix, the British pharma company’s shingles vaccine for people aged 50 years or older, was unanimously recommended for approval by a U.S. Food and Drug Administration (FDA) advisory panel last week. Older people are most at risk of an outbreak of shingles,…

U.S. States Plan Suit to Block Trump Obamacare Subsidies Cut

Yasmeen Abutaleb & Dan Levine  |  October 16, 2017

WASHINGTON/SAN FRANCISCO (Reuters)—On Friday, California, New York and others states vowed to sue President Donald Trump’s administration to stop him from scrapping a key component of Obamacare, subsidies to insurers that help millions of low-income people pay medical expenses, even as Trump invited Democratic leaders to negotiate a deal. One day after his administration announced…

  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 98
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences